eyeforpharma's 7th Annual Sales Force Effectiveness

eyeforpharmaeyeforpharma's 7th annual Sales Force Effectiveness, Princeton, May 4-5 2009 is borne out of ongoing in-depth research with hundreds of your peers. Seven VPs sit among a 30-strong speaker faculty to present on what we know are critical topics.

eyeforpharma is a leader in the Sales Force Effectiveness space worldwide and with nearly a decade of experience in this field, brings together elite audiences of leading industry executives to focus on the core issues.

Topics that will be covered:

  • SALES STRATEGY: Refocus your sales approach around your customer to succeed in a changing selling environment
  • TRAINING, DEVELOPMENT & LEADERSHIP: Examine innovative coaching models and develop your leadership ethos to ensure your sales force is continually evolving
  • SALES TOOLS AND TECHNOLOGY: Leverage your sales tools and data resources to streamline your technology
  • PHYSICIAN ACCESS: Connect directly with your customer. Engage with 5 key opinion leaders to ensure optimal communication and collaboration
  • A NEW COMMERCIAL MODEL: Evaluate what your company needs to achieve in a new model and hear practical techniques to ensure it expedites your sales objectives

For further information and registration, please visit:
http://www.eyeforpharma.com/sfeusa

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...